Astrana Health, Inc. (ASTH) AI Stock Analysis

Astrana Health, Inc., formerly known as Apollo Medical Holdings, Inc., is a physician-centric healthcare management company based in Alhambra, California. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement, powered by its proprietary population health management platform. This integrated framework coordinates care for patients, families, primary care providers, specialists, acute care hospitals, physician groups, and health plans. Astrana Health supports a value-based healthcare model across the United States, serving patients covered by Medicare, Medicaid, health maintenance organizations, private insurance, and uninsured individuals.

Astrana Health delivered a 5-year revenue CAGR of 53.8% from FY2020 to FY2025. Annual revenue grew from $773.9M in FY2021 to $1.14B in FY2022, $1.39B in FY2023, $2.03B in FY2024, and reached $3.18B in FY2025, representing a 56.4% year-over-year increase. However, operating margin narrowed from 12.7% in FY2021 to 2.5% in FY2025, while net margin declined from 8.9% to 0.7%, resulting in net income falling to $22.5M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 48.5% year-over-year, while quarterly earnings growth reached 110.5%. Trailing twelve months revenue stands at $3.84B with an operating margin of 3.5%.

As of June 30, 2026, Astrana Health held $400.8M in cash and short-term investments against total debt of $979.4M, resulting in net debt of $578.6M. The company reported shareholders' equity of $830.2M and total assets of $2.28B, yielding a debt-to-equity ratio of 1.18 and a current ratio of 1.23. In FY2025, operating cash flow reached $114.6M and free cash flow was $104.5M. Cash allocations in FY2025 included $10.1M in capital expenditures, $15.4M for share buybacks, and $7.9M in dividends paid.

ASTH trades at a trailing P/E of 44.3x, above the 24.6x median of its US-listed Healthcare peers. Its forward P/E is 9.0x compared to the peer median of 17.3x, and its price-to-sales multiple is 0.5x versus the peer median of 4.1x. The enterprise value to EBITDA ratio of 12.0x matches the peer median of 12.0x. Over the past year, the stock returned 15.8%, trailing the S&P 500 (SPY) return of 16.8%. Over a 5-year period, ASTH has a return of -48.5%, compared to an 83.0% gain for the benchmark.

Wall Street analysts display a positive stance on ASTH, with 8 Strong Buy, 2 Buy, and 1 Hold ratings. The mean price target of $51.67 implies 40.4% upside relative to the last close of $36.81. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $3.98B and EPS of $3.07, representing 44.5% EPS growth. Astrana Health has beaten EPS estimates in each of the last 4 quarters, and its next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of Astrana Health, Inc. (ASTH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ASTH income statement, ASTH balance sheet, ASTH key metrics, ASTH analyst forecast, ASTH chart. See the ASTH stock overview for the latest quote and news.